Drug Testing Industry Sees Steady Expansion
June 13, 2017
Wellesley, Mass., Jun 13, 2017 – Steadily growing demand for substance abuse test equipment is a building block for medical technology companies, according to a new report by BCC Research, which forecasts both new applications and growing new segments for home testing and school-based tests. From 2016 sales estimated at $3 billion, the industry is forecast to reach nearly $4 billion annually by 2022, according to Drug Testing: Technologies and Global Markets.
Test equipment using blood samples, hair, urine, and other methods has limitations, such as detecting the presence of drugs but difficult to show levels, intoxication or impairment. And most existing test kits can detect only drug classes – opiates, methadone, cocaine, cannabinoids etc. – not specific drugs or their sources such as whether they are smoked, eaten or injected, the BCC Research report explains.
The testing market is estimated at $2.2 billion in the US in 2017 and $563 million in the European Union. An industry CAGR of 4.5% through 2022 is expected with urine and blood tests remaining market leaders. Increasing use of saliva tests may see a sharper growth in that emerging segment, the report concluded. Multinational corporations in the industry include Abbott Diagnostics, Siemens Medical Solutions, Beckman Coulter, Alere and Roche Diagnostics.
Research Highlights
- Onsite testing by law enforcement and first responders is a smaller market, compared with laboratory-based complex testing, but growth has been steady as employers or state laws dictate a drug-free workplace.
- By the end of 2016, 29 U.S. states and Washington D.C. had decriminalized or legalized marijuana use yet it remains illegal under federal law. Federal drug tests are mandate for millions of workers from airline pilots and nuclear power workers to military personnel.
- The United Nations estimates the drug user population at more than 200 million people, with opiates and heroin the most popular globally. In South America, cocaine is the primary drug of abuse.
"Throughout the U.S., state governments are making drug testing a condition for receiving certain benefits payments and drug law offenses – along with overdoses -- are on the rise so there are health implications, legal issues and other factors complicating this industry,” says Robert G Hunter, Senior Editor Healthcare, BCC Research. "Testing has been growing more common since the 1980s and the U.S. has, by far, the greatest demand – both onsite and in laboratory.”
Editors and reporters who wish to speak with the analyst should contact Steven Cumming at steven.cumming@bccresearch.com.
Drug Testing: Technologies and Global Markets( PHM013G )
Publish Date: May 2017
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
More in Pharmaceuticals
- Global Hyaluronic Acid in Healthcare Market to Reach $10.5 Billion by 2030
- Targeted Alpha Therapies Market to Grow at 44% CAGR Globally by 2030
- Global Anti-Parkinson's Drugs Markets Projected to Reach $9.2 Billion by the End of 2030
- Rheumatoid Arthritis Therapies Market to Hit $41.1B by 2030
- Infectious Disease Therapies Market Projected to Reach $101 Billion by End of 2030
Reports from Pharmaceuticals
Recent News
- Global Patient Monitoring Market to Reach $55.8 Billion by End of 2030
- Biomarker Deals Accelerate: Strategic Alliances Reshape Life Sciences Innovation
- China’s DNA Sequencing Market to Grow at 21.5% CAGR by 2030
- Global Market for Biological and Medical Imaging Reagents Set to Surge to $40.1 Billion by 2030
- mRNA Market Forecast: Small Decline of -0.04% CAGR by 2030
